DaVita Inc. (DVA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several negative indicators: a decline in treatment volume, increased patient care costs, and a significant operating income shortfall. The reaffirmed EPS guidance is overshadowed by weak guidance on treatment volumes and RPT growth. The Q&A session highlights concerns over mortality rates, unpredictable IKC revenue timing, and the impact of a cyber incident. Despite some positive aspects like technology investments and debt management, the overall sentiment is negative, particularly with the lack of clear guidance and the market's reaction to these uncertainties.
Key Financial Performance
Adjusted Operating Income (Q3 2025) $517 million, consistent with internal expectations. U.S. treatment volume was down approximately 1.5% year-over-year due to factors like Hurricane Helene, severe flu season, and a cyber incident.
Adjusted Earnings Per Share (Q3 2025) $2.51, consistent with internal expectations.
Free Cash Flow (Q3 2025) $604 million, no year-over-year change or reasons mentioned.
U.S. Treatment Volume (Q3 2025) Declined 1.5% year-over-year. Reasons include higher mortality from a severe flu season, lost admissions opportunities due to Hurricane Helene, and a cyber incident.
Revenue Per Treatment (Q3 2025) Increased approximately $6 sequentially, driven by rate increases, higher revenue from phosphate binders, and recovery from the cyber incident in Q2. Offset by a slight decline in payer mix and normal variability.
Patient Care Costs Per Treatment (Q3 2025) Increased by approximately $5 sequentially due to typical wage increases and higher pharmaceutical expenses from increased dispensing of phosphate binders.
International Adjusted Operating Income (Q3 2025) $27 million, down $9 million sequentially due to a one-time benefit in the previous quarter.
Integrated Kidney Care (IKC) Adjusted Operating Loss (Q3 2025) $21 million, with quarterly phasing hard to forecast. Expected to achieve flat or better results for 2025 compared to 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DaVita Clinical Research (DCR): DCR has over 250 research sites in the U.S., conducted 500+ clinical trials, contributed to FDA approval of dozens of ESKD drugs, and fueled 700+ clinical publications. It is currently evaluating middle molecule clearance using middle cut-off dialyzers, which could significantly advance patient outcomes.
U.S. Dialysis Treatment Volume: Treatment volume declined 1.5% year-over-year due to factors like Hurricane Helene, a severe flu season, and a cyber incident. Revenue per treatment increased by $6 sequentially, driven by rate increases and higher revenue from phosphate binders.
Technology Investments: Investments in IT infrastructure include enhancing the next-generation clinical platform, replacing the scheduling system, upgrading revenue operations technology, and adopting AI solutions to improve clinical care and cost efficiencies.
Cost Management: Patient care costs per treatment increased by $5 sequentially, mainly due to wage increases and higher pharmaceutical expenses. However, costs continue to outperform expectations.
Integrated Kidney Care (IKC): Awaiting final 2024 performance year results from the CKCC program. Timing of operating income recognition could shift between 2025 and 2026. Efforts are ongoing to achieve flat or better IKC adjusted operating results in 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Government Shutdown and Policy Uncertainty: The ongoing government shutdown and key healthcare policy decisions in flux could have real implications for the company, potentially affecting operations and financial performance.
Decline in U.S. Treatment Volume: U.S. treatment volume was down approximately 1.5% year-over-year, attributed to factors such as Hurricane Helene, a severe flu season, and a cyber incident, which negatively impacted patient admissions and census trends.
Payer Mix and Policy Changes: Active policy debates and recalibration of the Medicare Advantage landscape, including the impact of enhanced premium tax credits and evolving government policies, could affect the company's insurance mix and financial outcomes.
Cyber Incident: A cyber incident earlier in the year disrupted operations, leading to lost admissions opportunities and impacting revenue per treatment in the second quarter.
Higher General and Administrative (G&A) Costs: Investments in technology infrastructure, including AI solutions and upgrades to clinical and revenue operations systems, are driving higher G&A growth, which could pressure margins in the short term.
Integrated Kidney Care (IKC) Revenue Timing: The timing of operating income recognition from the government CKCC program remains uncertain, creating variability in financial results for 2025 and 2026.
Patient Care Costs: Patient care costs per treatment increased by approximately 5% to 6% year-over-year, driven by wage increases and higher pharmaceutical expenses, which could impact profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2025 Guidance: Reaffirmed midpoint of guidance ranges for adjusted operating income ($2.035 billion to $2.135 billion) and adjusted earnings per share ($10.35 to $11.15).
2026 Key Variables: Several factors will influence 2026 performance, including treatment volume recovery from 2025 headwinds (Hurricane Helene, severe flu season, cyber incident), payer mix changes due to policy debates, and timing of Integrated Kidney Care (IKC) program results.
Revenue Per Treatment (RPT) Growth: Expected to be at the low end of the original 4.5% to 5.5% guidance for 2025, with anticipated acceleration in Q4 driven by vaccines, rate increases, and resolution of aged claim balances.
Patient Care Costs (PCCs) Per Treatment: Projected to increase between 5% and 6% for 2025 compared to 2024.
Integrated Kidney Care (IKC) Business: Anticipates flat or better adjusted operating results in 2025 compared to 2024, with timing of revenue recognition potentially shifting between 2025 and 2026.
Fourth Quarter 2025 Outlook: Sequential improvement expected, driven by higher treatment volume, increased revenue per treatment, and timing of IKC revenue, offset by seasonal increases in patient care costs and G&A.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: During the third quarter, DaVita repurchased 3.3 million shares and an additional 400,000 shares since the end of the quarter. Year-to-date, approximately 10 million shares have been repurchased, representing approximately $1.5 billion. The 400,000 shares repurchased in October were pursuant to a publicly filed repurchase agreement with Berkshire Hathaway, which is contractual and formulaic, ensuring Berkshire's ownership remains at 45%.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How do you think volumes would have played out this year excluding the hurricane, cyber, and flu impacts?
A:The CFO estimated a 75 to 100 basis point headwind on 2025 volume from these three factors combined, affecting census and missed treatment rates.
Q:Can you provide more color on efforts to improve mortality?
A:The CEO mentioned that improving mortality is a steady process over time, involving clinical protocols, time on therapy, fluid management, GLP-1s, and other medications. Mid-molecule clearance will also be addressed in the future.
Q:What is the significance of MA enrollment as a swing factor for 2026?
A:The CEO explained that MA enrollment is dynamic and could significantly impact revenue due to payer mix and enrollment volatility. However, commercial mix is a more significant financial swing factor than MA mix.
Q:Is the 75 to 100 basis points of discrete items a reasonable starting point for next year's growth?
A:The CFO confirmed that 75 to 100 basis points is a reasonable starting point for 2025 to 2026 growth, with structural improvements of 50 to 75 basis points expected in 2026.
Q:What impact will investments in technology and infrastructure have on treatment growth?
A:The CEO stated that while specific volume impacts are uncertain, investments in risk stratification for hospitalization and administrative efficiencies could positively influence volume and cost structure.
Q:Is the $120 million headwind from premium tax credits over three years still accurate?
A:The CEO confirmed the estimate, with $40 million in year 1, $70 million in year 2, and $10 million in year 3, depending on Congressional actions.
Q:What caused the $50 million operating income shortfall compared to consensus?
A:The CFO attributed the shortfall to mismodeling by analysts due to day count differences and highlighted a $60 million uplift needed in Q4 to meet guidance.
Q:What was the impact of the cyber-attack and Mozarc relationship on earnings?
A:The CFO stated that the Mozarc charge will largely eliminate its drag on next year's P&L, while the cyber-attack's impact has diminished, primarily affecting volume.
Q:How did new patient starts and mortality trend in Q3?
A:The CFO reported no significant changes in new patient starts or mortality trends, with admissions running within the normal post-COVID band.
Q:What is the timing of IKC funds and its impact?
A:The CFO explained that IKC revenue timing is unpredictable and depends on information from payers and the federal government, with some revenue shifted to Q2 this year.
Q:What factors contribute to the wide Q4 guidance range?
A:The CFO cited RPT and IKC variability as key factors, with treatment volume growth expected to be around 20 to 30 basis points year-over-year.
Q:What is the current market share and its trend?
A:The CFO stated that market share data is limited, but adjustments for cyber-attack impacts suggest no meaningful shift in market share.
Q:What is the sequential improvement in RPT for Q4?
A:The CFO estimated an $8 improvement in RPT, with more than half attributed to favorable resolution of older claims.
Q:What is the current commercial treatment mix?
A:The CFO reported the commercial treatment mix at around 11%, down 15 basis points from the previous quarter.
Q:What is the status of revenue cycle improvements?
A:The CFO stated that revenue cycle improvements are ongoing, with opportunities for automation and AI to enhance collections, despite a slowdown due to the cyber incident.
Q:Review of Unclear Management Responses
A:Management avoided directly answering questions about the specific impact of IOTA on treatment growth and the exact market share changes excluding the cyber incident. They also used vague language when discussing the variability in IKC timing and the potential Congressional actions on premium tax credits.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI solution
Advantage enrollment
Advantage landscape
Care IKC
Clinical Research
DCR director
DCR kidney
DCR outcome
DCR research
DCR therapy
ESKD drug
FDA approval
GA investment
Helene flu
IKC release
Joel detail
Medicare Advantage
Research DCR
States trial
Today research
ability Joel
ability patient
application provider
approval dozen
behavior Medicare
benefit patient
care environment
development
government
health care
income share
kidney care
payer
perspective
platform
progress
teammate
technology
term investment
variable
DVA Transcript
DaVita Inc. (DVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
DaVita Inc. (DVA) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call summary shows modest growth in revenue, operating income, and net income, with improvements in free cash flow. However, the absence of strategic initiatives or operational updates, coupled with a lack of clarity in management's responses during the Q&A, suggests limited catalysts for significant stock movement. The overall sentiment is neutral as the financial performance is stable but not strong enough to drive a positive stock reaction, and there are no negative surprises to warrant a negative reaction.
DaVita Inc. (DVA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript
Unknown2-2
The earnings call presents mixed signals. While the company has achieved milestones, such as the first profitable year for IKC and strong international growth, challenges remain. The Q&A highlights concerns about ACA headwinds, missed treatments, and uncertainty in patient volume growth. Management's unclear responses to certain questions add to the uncertainty. Although there are positive elements, like reaffirmed guidance and strategic investments, the mixed financial outlook and external challenges suggest a neutral stock price movement in the short term.
DVA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
